|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
FDA Office of Orphan Products Development Charles Drew University of Medicine and Science |
| Information provided by: | FDA Office of Orphan Products Development |
| ClinicalTrials.gov Identifier: | NCT00004400 |
Purpose
OBJECTIVES: I. Determine whether physiologic testosterone replacement can increase fat-free mass, therefore contributing to weight maintenance, improved muscle function, and quality of life in HIV-infected women.
II. Examine the mechanism of testosterone-induced increase in fat-free mass.
| Condition | Intervention | Phase |
|
HIV Infections Cachexia |
Drug: testosterone |
Phase II |
| MedlinePlus related topics: | AIDS |
| Drug Information available for: | Testosterone Methyltestosterone Oxymesterone Testosterone enanthate Testosterone Propionate Testosterone undecanoate |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Efficacy Study |
| Estimated Enrollment: | 56 |
| Study Start Date: | April 1997 |
PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled study. Patients are randomized to one of three arms.
Arm I: Patients receive two placebo transdermal patches applied twice a week (every 3-4 days).
Arm II: Patients receive one testosterone transdermal patch and one placebo transdermal patch applied twice a week (every 3-4 days).
Arm III: Patients receive two testosterone transdermal patches applied twice a week (every 3-4 days).
Patients receive 12 weeks of treatment in the absence of adverse reaction or health deterioration. Patients are followed on day 1, every 2 weeks during treatment, and at the end of the recovery period. Quality of life is assessed before treatment begins and at weeks 6 and 12.
Eligibility
| Ages Eligible for Study: | 18 Years to 50 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
--Prior/Concurrent Therapy--
--Patient Characteristics--
Contacts and Locations| United States, California | |||||
| Charles R. Drew University of Medicine and Science | Recruiting | ||||
| Los Angeles, California, United States, 90059 | |||||
| Contact: Shalender Bhasin 213-563-9353 | |||||
| Los Angeles County Harbor-UCLA Medical Center | Recruiting | ||||
| Torrance, California, United States, 90509 | |||||
| Contact: G. Beall 310-222-2444 | |||||
| United States, Missouri | |||||
| Washington University School of Medicine | Recruiting | ||||
| Saint Louis, Missouri, United States, 63110 | |||||
| Contact: K. Yarashaski 314-362-9700 | |||||
| FDA Office of Orphan Products Development |
| Charles Drew University of Medicine and Science |
| Study Chair: | Shalender Bhasin | Charles Drew University of Medicine and Science |
More Information
| Study ID Numbers: | 199/13251, CDUMS-FDR001397 |
| First Received: | October 18, 1999 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00004400 |
| Health Authority: | United States: Federal Government |
|
|
|
|
|
|